Borui Pharmaceuticals: Subsidiary BGM0504 Tablet Clinical Trial Approved.

Borui Pharmaceuticals announced on September 15th that its wholly-owned subsidiary, Borui Pharmaceutical Co., Ltd., recently received a "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, permitting the clinical trial of BGM0504 tablets in overweight/obese adults.